A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
Yuji Minegishi, Akihiko Gemma(Nippon Medical School), Osamu Hataji(Soka Municipal Hospital), Ou Yamaguchi(Saitama International Medical Center), Shoichi Kuyama(Iwakuni Medical Center), Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiro Usui(Hokkaido University Hospital), Satoshi Morita(Kyoto University), Masahide Mori(Toneyama National Hospital), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Toshihiro Nukiwa(Tohoku University), Kunihiko Kobayashi(Saitama International Medical Center)
Cited by 18
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953